Showing results (1-10 of 350) with videos related to

Sort By:
Pageof 35
Journal of Internal Medicine|May 16, 2000
The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study GroupP Lindmarker, S Schulman
The New England Journal of Medicine|June 30, 2000
Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation TrialS Schulman, P Lindmarker
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 1, 1995
Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolismS Schulman, P Lindmarker, H Johnsson
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 16, 2002
A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disordersS Schulman, N Kinnman, P Lindmarker, et al.
Thrombosis and Haemostasis|June 12, 1999
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of AnticoagulationP Lindmarker, S Schulman, M Sten-Linder, et al.
Haemostasis|January 12, 2000
Can all patients with deep vein thrombosis receive low-molecular-weight heparin in an outpatient setting?P Lindmarker
Journal of Internal Medicine|December 1, 1996
Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial GroupP Lindmarker, M Holmström
Journal of Thrombosis and Haemostasis : JTH|January 18, 2006
Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesisA Agren, B Wiman, V Stiller, et al.
The New England Journal of Medicine|June 22, 1995
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study GroupS Schulman, A S Rhedin, P Lindmarker, et al.
The New England Journal of Medicine|February 6, 1997
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study GroupS Schulman, S Granqvist, M Holmström, et al.
Pageof 35